Up-Regulated FGFR1 Expression as a Mediator of Intrinsic TKI Resistance in EGFR-Mutated NSCLC

Non-small cell lung carcinoma patients with epidermal growth factor receptor (EGFR) mutations are offered EGFR tyrosine kinase inhibitors (TKI) as first line treatment, but 20–40% of these patients do not respond. High expression of alternative receptor tyrosine kinases, such as Fibroblast growth fa...

Descripción completa

Detalles Bibliográficos
Autores principales: Gammelgaard, Kristine Raaby, Vad-Nielsen, Johan, Clement, Michelle Simone, Weiss, Simone, Daugaard, Tina Fuglsang, Dagnæs-Hansen, Frederik, Meldgaard, Peter, Sorensen, Boe Sandahl, Nielsen, Anders Lade
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Neoplasia Press 2018
Materias:
Original article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6297127/
https://www.ncbi.nlm.nih.gov/pubmed/30562682
http://dx.doi.org/10.1016/j.tranon.2018.11.017

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6297127/
https://www.ncbi.nlm.nih.gov/pubmed/30562682
http://dx.doi.org/10.1016/j.tranon.2018.11.017

Ejemplares similares